All News
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Can Neural Networks Answer Important Diagnostic Dilemmas in Rheumatology?
An interesting study presented at ACR22 looked at whether neural networks can distinguish seropositive rheumatoid arthritis (RA+), seronegative RA (RA-), and psoriatic arthritis (PsA) using hand MRI data based on the structural inflammation patterns.
Read Article
Deane et al STOP RA trial. DBRCT HCQ vs PBO pre-RA. Treat 1 year, stop, 2 year follow up. Does not prevent RA development. Literally no effect at all, even during treatment phase. @RheumNow #ACR22 Abstr#1604 https://t.co/7jHv7cs5DT https://t.co/GNblKs90RU
Richard Conway RichardPAConway ( View Tweet)
Charlton et al PsA patients face longer diagnostic delay and less intensive treatment than RA patients for equivalent disease activity. @RheumNow #ACR22 Abstr#1613 https://t.co/HedK59QsKs https://t.co/xaJUy7w1t4
Richard Conway RichardPAConway ( View Tweet)
Preventing #rheumatoid #arthritis - the holy grail! STOPRA RCT of strong ACPA+; CCP3 high titre. No inflammatory arthritis. RCT of #Hydroxychloroquine vs placebo, N=142 Pts. At 3 yrs NO DIFF in onset@of RA in each group. identical curves. Abst1604 #ACR22 #ACRBest @RheumNow Darn! https://t.co/bEgbkxGSR4
Janet Pope Janetbirdope ( View Tweet)
Abs 1417 finds physicians prefer ABA over TNFi for RF/ACPA+ pts w/ higher disease severity, older age, the presence of extra-articular manifestations, and comorbidities such as heart failure. My question: Trouble getting it first line? #ACR22 @RheumNow https://t.co/tlFMgjgDNM https://t.co/ukoeLgSSUd
Dr. Rachel Tate uptoTate ( View Tweet)
In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO
Dr. Rachel Tate uptoTate ( View Tweet)
Look at these graphs and try and tell me that sex and gender doesn't matter in RA.
We have seen in study after study after study - sex and gender matters.
ABST0241 @erasmusmcintl #ACR22 @RheumNow https://t.co/GQnKrAp0eB https://t.co/MxHRy2kwDN
David Liew drdavidliew ( View Tweet)
Pre-RA studies: a summary by Dr. Deane #ACR22 @RheumNow https://t.co/HU8JWmYM8H
David Liew drdavidliew ( View Tweet)
HCQ does not prevent RA in CCP+ pts w/out clinical arthritis!
Stop RA: RCT HCQ vs. PBO in pts at-risk
Interim analysis 140+ pts
RA development HCQ 34% vs. PBO 36%
Trial interrupted as met futility criteria.
https://t.co/n31OmsjLhM
Abs#1604 #ACR22 @RheumNow #ACRBest https://t.co/NVYS8kB5to
Aurelie Najm AurelieRheumo ( View Tweet)
2022 ACR G/L for Integrative RA Intervent #ACR22
1 strong rec: consistent exercisee
27 conditional recs:
Rehab, Mediterr diet, against other diets, self-mgmt/CBT/acupunct
Conditional against electrotherapy, chiropractor
No rec for diet supplem
BMI, 🚬: no RA spec recomm
@RheumNow https://t.co/cVFr6beQuJ
Eric Dein ericdeinmd ( View Tweet)
Joerns et al. Baseline IL-17 higher in RD-ILD vs IPF. Low IL-13 assoc shorter progression free survival HR 17.36 @RheumNow #ACR22 Abstr#1109 https://t.co/I8R3SrxNfV https://t.co/he1A3SYDp0
Richard Conway RichardPAConway ( View Tweet)
Does curcumin help maintain drug-free remission RA?
Answer is No
Single center RCT Curcumin vs PBO w/ MTX withdrawal
= flare-free survival
= median time to flare (219 d vs. 214 d)
Serum curcuminoid levels not asso w/ flares
https://t.co/3U6W0Iuqrq
Abs#1587 #ACR22 @Rheumnow https://t.co/GwAsY7OKTX
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
TOFA and MTX: which one to withdraw first?
RCT in 100+ RA pts in remission after 1 yr, 1 yr follow-up
Withdraw MTX grp: Remission 30% LDA 40%
Withdraw TOFA grp: Remission 50% LDA 65%
diff NS small sample
8 SAEs, 72% recovery
https://t.co/tMnet32TWF
Abs#1586 #ACR22 @Rheumnow https://t.co/PWnkWYdlGk
Aurelie Najm AurelieRheumo ( View Tweet)
What to do next? Dazodalibep Rx in bDMARDs IR #RA pts. Dazo is a novel CD40 ligand antagonist Phase II RCT. N=78, multi dose phase II RCT. All doses improved DAS28. Dosing interval may be prolonged over time. Awaiting phase 3. Abst#2008 #ACR22 @RheumNow https://t.co/IrzflycKZp
Janet Pope Janetbirdope ( View Tweet)
⬆️ serum anti-CCP3 Ab, absence IA
👉 StopRA trial - ironically stopped🛑
❌ hydroxychloroquine not superior to PBO in preventing/ delaying IA
👉rate of conversion to RA in CCP3+ve ~35% @ 3yrs
#ACR22 @RheumNow Abst#1604
Patricia Harkins DrTrishHarkins ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al Excess of rare variants in JAK-STAT genes in RA-ILD vs RA 57% vs 46%;OR=1.37 95%CI[1.12-1.69]. Elucidates pathophysiology but also possible treatment rationale @RheumNow #ACR22 Abstr#1123 https://t.co/TAA0rODSmV https://t.co/2TjSY4CXDL
Richard Conway RichardPAConway ( View Tweet)
#Abs1260 #acr22 @rheumnow #acrbest Clincial&US eval 54 RA &18 PsA pts: Tenderness aasoctd w/radiographic progress in non-swollen jnts in PsA but not in RA. In tender non-swollen jnts in RA pts, baseline erosions& sonographic synovitis had significant impact on radio progression https://t.co/iqWvHiDeq8
Olga Petryna DrPetryna ( View Tweet)
Uggh!
What would you do if your pt gets pregnant while on MTX & loses her baby, are you liable for accidental abortion? Should you advise termination if a pregnant pt’s health is deteriorating? @GreerDonley (#law professor) on theoretical risks #ACR22 @rheumnow https://t.co/L4FBWcKZnE
TheDaoIndex KDAO2011 ( View Tweet)
Doyen et al. FIND-RA study. RA for >1<10 years. RA-ILD 12%, air trapping 58%, rheumatoid nodules 11%. @RheumNow #ACR22 Abstr#1393 https://t.co/Sy1qwZJq5E https://t.co/ww8HgHT32E
Richard Conway RichardPAConway ( View Tweet)
